UBS Maintains Neutral on Teladoc Health, Raises Price Target to $9
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Kevin Caliendo maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $6.5 to $9.
UBS analyst Kevin Caliendo maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $6.5 to $9.